SCHEMBL6801869

SCHEMBL6801869

CCOC(=O)c1c[nH]c(C)n1

nearest known ligand 0.55

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.55
MEN1 O00255 4/20 0.46
KMT2A Q03164 4/20 0.46
ALDH1A1 P00352 4/20 0.46
MAPT P10636 2/20 0.46
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46
KDM4E B2RXH2 3/20 0.42
CYP2C19 P33261 1/20 0.42
GAA P10253 1/20 0.42
POLB P06746 2/20 0.41
MAPK1 P28482 1/20 0.41
TSHR P16473 1/20 0.41
HPGD P15428 1/20 0.41
PDE4D Q08499 1/20 0.41
GABRA2 P47869 1/20 0.40
GABRB2 P47870 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20268120 0.88 ALDH1A1 (0.43) CYP1A2MEN1KMT2AALDH1A1MAPT
SCHEMBL3809367 0.84 CYP1A2 (0.53) CYP1A2MEN1KMT2AALDH1A1MAPT
SCHEMBL165586 0.84 CYP1A2 (0.53) CYP1A2MEN1KMT2AALDH1A1MAPT
SCHEMBL27309405 0.82 CYP1A2 (0.51) CYP1A2MEN1KMT2AALDH1A1MAPT
SCHEMBL1407854 0.82 CYP1A2 (0.51) CYP1A2MEN1KMT2AALDH1A1MAPT
SCHEMBL24520477 0.82 CYP1A2 (0.51) CYP1A2MEN1KMT2AALDH1A1MAPT
SCHEMBL27348210 0.82 CYP1A2 (0.51) CYP1A2MEN1KMT2AALDH1A1MAPT
SCHEMBL269623 0.82 CYP1A2 (0.51) CYP1A2MEN1KMT2AALDH1A1MAPT
SCHEMBL692975 0.81 MAPK1 (0.43) CYP1A2MEN1KMT2AALDH1A1MAPT
Hydrochloric Acid SCHEMBL31378506 0.81 CYP1A2 (0.50) CYP1A2MEN1KMT2AALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12509470-B2 Antiviral heterocyclic compounds ENANTA PHARMACEUTICALS, INC. (US) 2025-12-30 US disclosed
US-12479842-B2 Pyrido[3,2-d]pyrimidine compounds uses thereof for treating a proliferative disease UNIVERSITE DE MONTREAL (CA) 2025-11-25 US disclosed
US-20250270207-A1 PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE UNIVERSITE DE MONTREAL (CA) 2025-08-28 US disclosed
US-12139488-B2 Pyrido[3,2-d]pyrimidine compounds uses thereof for treating a proliferative disease Université de Montréal (CA) 2024-11-12 US disclosed
US-20240317747-A1 PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE Université de Montréal (CA) 2024-09-26 US disclosed
US-12060353-B2 Pyrido[3,2-d]pyrimidine compounds uses thereof for treating a proliferative disease Université de Montréal (CA) 2024-08-13 US disclosed
US-20240217971-A1 PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE Université de Montréal (CA) 2024-07-04 US disclosed
US-12006326-B2 Antiviral heterocyclic compounds ENANTA PHARMACEUTICALS, INC. (US) 2024-06-11 US disclosed
US-20240140945-A1 PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE Université de Montréal (CA) 2024-05-02 US disclosed
EP-4326719-A1 PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE Université de Montréal (CA) 2024-02-28 EP disclosed
US-20090105208-A1 Substituted Piperazines as CB1 Antagonists SCHERING CORPORATION 2009-04-23 US disclosed
WO-2009005646-A2 SUBSTITUTED PIPERAZINES AS CB1 ANTAGONISTS SCHERING CORPORATION (US) 2009-01-08 WO disclosed
US-20040097508-A1 Novel heterocyclically substituted amides, their preparation and use ABBOTT GMBH & CO. KG (DE) 2004-05-20 US disclosed
US-6630493-B1 Inhibitors of capain enzymes useful for the treatment of ischemias of the heart, the kidney or of central nervous system (e.g. \"stroke\"), inflammations, muscular dystrophy, cataracts of the eyes, Alzheimer's disease etc. BASF AKTIENGESELLSCHAFT (DE) 2003-10-07 US disclosed
EP-0397365-B1 Arylthiazolylimidazoles as 5HT3 Antagonists PFIZER (US) 1994-03-02 EP disclosed
US-5207820-A Crop protection agents based on 1-aryl- or 1-hetarylimidazose carboxylic esters BASF AKTIENGESELLSCHAFT (DE) 1993-05-04 US disclosed
US-5043454-A Antidotes used with herbicides BASF AKTIENGESELLSCHAFT (DE) 1991-08-27 US disclosed
EP-0397365-A1 Arylthiazolylimidazoles as 5HT3 Antagonists PFIZER INC. (US) 1990-11-14 EP disclosed
US-4914207-A ANTIEMETICS PFIZER INC. (US) 1990-04-03 US disclosed
EP-0008596-A1 Preparation of 4-hydroxymethyl-imidazole derivatives from the corresponding 4-imidazole carboxylic acid esters DEVINTER Europe S.A. Société anonyme dite: (BE) 1980-03-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250270207-A1 PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE BRAF, NRAS, KRAS CYP1A2 2314/4885MEN1 1789/4885KMT2A 2292/4885
US-20040097508-A1 Novel heterocyclically substituted amides, their preparation and use CAPN1, CAPNS1, CAPN2 CYP1A2 2635/4885MEN1 4075/4885KMT2A 4109/4885
US-20240140945-A1 PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE BRAF, NRAS, KRAS CYP1A2 2314/4885MEN1 1789/4885KMT2A 2292/4885
US-12509470-B2 Antiviral heterocyclic compounds NR3C1, ZC3HAV1, HAVCR2 CYP1A2 2797/4885MEN1 2420/4885KMT2A 2895/4885
US-20240317747-A1 PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE BRAF, NRAS, KRAS CYP1A2 2314/4885MEN1 1789/4885KMT2A 2292/4885
US-12139488-B2 Pyrido[3,2-d]pyrimidine compounds uses thereof for treating a proliferative disease BRAF, NRAS, KRAS CYP1A2 2314/4885MEN1 1789/4885KMT2A 2292/4885
US-12060353-B2 Pyrido[3,2-d]pyrimidine compounds uses thereof for treating a proliferative disease BRAF, NRAS, KRAS CYP1A2 2314/4885MEN1 1789/4885KMT2A 2292/4885
US-20090105208-A1 Substituted Piperazines as CB1 Antagonists CNR1, CNR2, GPR119 CYP1A2 475/4885MEN1 2811/4885KMT2A 1954/4885
US-12479842-B2 Pyrido[3,2-d]pyrimidine compounds uses thereof for treating a proliferative disease BRAF, NRAS, DPYD CYP1A2 2263/4885MEN1 1888/4885KMT2A 2305/4885
US-12006326-B2 Antiviral heterocyclic compounds ACE, HPRT1, ACE2 CYP1A2 1080/4885MEN1 1038/4885KMT2A 2570/4885
US-20240217971-A1 PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE BRAF, NRAS, DPYD CYP1A2 2263/4885MEN1 1888/4885KMT2A 2305/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.